Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Lymphoma, Follicular 17Lymphoma, Large B-Cell, Diffuse 9Sarcoma 7Lymphoma, B-Cell 7Lymphoma, Non-Hodgkin 6Rhabdoid Tumor 5Lymphoma 5Sarcoma, Synovial 4Prostatic Neoplasms 4Recurrence 3Mesothelioma 3Lymphoma, Mantle-Cell 3Wilms Tumor 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Hematologic Neoplasms 2Glioma 2Ependymoma 2Central Nervous System Neoplasms 2Xanthogranuloma, Juvenile 1Urinary Bladder Neoplasms 1

Interventions

Nivolumab 6Imatinib Mesylate 4Ipilimumab 3Cetuximab 3pembrolizumab 2palbociclib 2Specimen Handling 2Radiotherapy 2Radiosurgery 2Protons 2Proton Therapy 2Pemetrexed 2Magnetic Resonance Spectroscopy 2Cyclophosphamide 2tazemetostat 1spartalizumab 1relatlimab 1nilotinib 1camrelizumab 1avelumab 1atezolizumab 1apatinib 1Zoledronic Acid 1X-Rays 1Tiragolumab 1Thiotepa 1Radiotherapy, Intensity-Modulated 1Radiation 1Photochemotherapy 1Phantoms, Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Chordoma × tazemetostat × Clear all
NCT05407441 2026-04-13

Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

Dana-Farber Cancer Institute

Phase 1/2 Active not recruiting
49 enrolled
Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡